Literature DB >> 6049299

In vitro antibacterial activity of kasugamycin.

A A Levitan.   

Abstract

Kasugamycin is an aminoglycosidic antibiotic which was initially reported as being of potential use against Pseudomonas. Our evaluation of this antibiotic does not confirm this expectation. The median minimal inhibitory concentration (MIC) of the Pseudomonas strains tested was 250 mug/ml and the bactericidal level was 500 mug/ml. Kasugamycin was found to be slightly more active in a more basic medium (Mycin Assay broth) in which the median MIC for 11 Pseudomonas strains was 125 mug/ml. Kasugamycin manifests a modest degree of serum binding. Kasugamycin did not have any appreciable effect against a variety of bacteria tested. The only exceptions were several species of gram-negative bacteria, against which more satisfactory antibiotics already exist. Further evaluation of kasugamycin for potential human use as an antipseudomonal agent does not appear warranted.

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 6049299      PMCID: PMC547053          DOI: 10.1128/am.15.4.750-753.1967

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  7 in total

1.  PHARMACOLOGY OF KASUGAMYCIN AND THE EFFECT ON PSEUDOMONAS INFECTION.

Authors:  T TAKEUCHI; M ISHIZUKA; H TAKAYAMA; K KUREHA; M HAMADA; H UMEZAWA
Journal:  J Antibiot (Tokyo)       Date:  1965-03       Impact factor: 2.649

2.  ANTIMICROBIAL ACTIVITY OF KASUGAMYCIN.

Authors:  M HAMADA; T HASHIMOTO; T TAKAHASHI; S YOKOYAMA; M MIYAKE; T TAKEUCHI; Y OKAMI; H UMEZAWA
Journal:  J Antibiot (Tokyo)       Date:  1965-03       Impact factor: 2.649

3.  A NEW ANTIBIOTIC, KASUGSMYCIN.

Authors:  H UMEZAWA; Y OKAMI; T HASHIMOTO; Y SUHARA; M HAMADA; T TAKEUCHI
Journal:  J Antibiot (Tokyo)       Date:  1965-03       Impact factor: 2.649

4.  Actinospectacin: an in vitro study of effectiveness against pathogenic bacteria.

Authors:  J W HALL; E ORTH
Journal:  Am J Med Sci       Date:  1962-07       Impact factor: 2.378

5.  Comparison of methods for determining sensitivity of bacteria to antibiotics in vitro.

Authors:  G G JACKSON; M FINLAND
Journal:  AMA Arch Intern Med       Date:  1951-10

6.  Kasugamycin treatment of Pseudomonas infection of the urinary tract.

Authors:  T Ichikawa
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1965

7.  Chemical studies on kasugamycin. V. The structure of kasugamycin.

Authors:  Y Suhara; K Maeda; H Umezawa
Journal:  Tetrahedron Lett       Date:  1966-03       Impact factor: 2.415

  7 in total
  3 in total

1.  Bactericidal Compounds Controlling Growth of the Plant Pathogen Pseudomonas syringae pv. actinidiae, Which Forms Biofilms Composed of a Novel Exopolysaccharide.

Authors:  Shirin Ghods; Ian M Sims; M Fata Moradali; Bernd H A Rehm
Journal:  Appl Environ Microbiol       Date:  2015-04-03       Impact factor: 4.792

2.  Kasugamycin Is a Novel Chitinase 1 Inhibitor with Strong Antifibrotic Effects on Pulmonary Fibrosis.

Authors:  Jae-Hyun Lee; Chang-Min Lee; Joyce H Lee; Mun-Ock Kim; Jin Wook Park; Suchitra Kamle; Bedia Akosman; Erica L Herzog; Xue Yan Peng; Jack A Elias; Chun Geun Lee
Journal:  Am J Respir Cell Mol Biol       Date:  2022-09       Impact factor: 7.748

3.  ksgA mutations confer resistance to kasugamycin in Neisseria gonorrhoeae.

Authors:  Paul M Duffin; H Steven Seifert
Journal:  Int J Antimicrob Agents       Date:  2008-12-18       Impact factor: 5.283

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.